1Y Target$91.59Near-term target
5Y Target$113.49Compound horizon
10Y Target$144.87Long-dated conviction
FCF$610mTTM · 03/26C+FCF $610m — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+23.5%TTM YoYA-Revenue +23.5% — strong growth, well above S&P median (~7%) · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.03totalAD/E 0.03 — essentially debt-free, pristine balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E19.6xBP/E 19.6 — moderate premium, defensible with growth
PEG0.83proxyB+PEG 0.83 — near fair value, classic Lynch benchmark (1.0) · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Health Care · market cap $11.5b. 16% off the 52-week high of $101.40. Revenue growing +23%, comfortably above the S&P median. PEG 0.83 — paying under fair value for the growth rate.
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon
1-3 yr $91.59 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $113.49 at ~6% CAGR — dividend + buyback compounding. 10 yr $144.87 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.